Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer

Executive Summary

Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.

You may also be interested in...



Disappointment For Novartis As England’s NICE Says No To Migraine Drug Again

New cost-effectiveness analyses and an improved deal for Aimovig have failed to change the health technology assessment body's mind about routine funding for the migraine prevention drug.

Novartis Bemused As NICE Says No Again To Migraine Drug Aimovig

The Swiss major is evaluating whether or not there is a case to appeal after the cost watchdog said it is “very uncertain" whether the CGRP inhibitor is more clinically effective for migraine than Botox.

Novartis Gets NICE Headache From Aimovig Knockback

The cost-effectiveness watchdog is worried about the cost of Novartis's once-monthly first-in-class migraine drug and is not convinced it is more effective than Allergan’s Botox, which can require up to 40 injections into the head and neck.

Topics

Related Companies

UsernamePublicRestriction

Register

PS125088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel